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’ INTRODUCTION
Carbonic anhydrase (CA, EC 4.2.1.1) IX (CA IX) has recently
been shown to be a druggable target for imaging and treatment
of hypoxic tumors overexpressing this protein.1-6 CA IX is the
most strongly overexpressed gene in response to hypoxia in
human cancer cells.2-4 This enzyme is a multidomain protein2
with the CA subdomain situated outside the cell and possessing
a very high CO2 hydrase catalytic activity,
7 making it a key
player in the regulation of tumor pH.1-6 CA IX expression is
strongly increased in many types of solid tumors, such as
gliomas/ependymomas, mesotheliomas, and papillary/follicular
carcinomas; carcinomas of the bladder, uterine cervix, kidneys,
esophagus, lungs, head and neck, breast, brain, and vulva; and
squamous/basal cell carcinomas.8,9 Furthermore, such hypoxic
tumors do not generally respond to the classic chemo- and
radiotherapy.8,9
Pouyssegur’s group showed recently5 that in hypoxic LS174Tr
tumor cells expressing either CA IX or both CA IX and CA XII
isoforms, in response to a CO2 load, both enzymes contribute to
extracellular acidification and to maintaining a more alkaline
resting intracellular pH (pHi), an action that preserves ATP
levels and cell survival in a range of acidic outside pH (6.0-6.8)
and low bicarbonate medium. In vivo experiments showed that
silencing of CA IX alone leads to a 40% reduction in xenograft
tumor volume, with up-regulation of the second gene, that
encoding for CA XII. Silencing of both CA IX and CA XII
gave an impressive 85% reduction of tumor growth.5 Hypoxia-
induced CA IX and CA XII are major tumor prosurvival pH-
regulating enzymes, and their combined inhibition held potential
for the design of anticancer drugs with a novel mechanism of
action. The in vivo proof-of-concept study that sulfonamide CA
IX inhibitors may indeed show antitumor effects has been only
very recently published by Neri’s group.6a Membrane-imperme-
able derivatives based on the acetazolamide AAZ scaffold to
which either fluorescein carboxylic acid or albumin-binding
moieties were attached have been employed. A strong tumor
growth retardation in animals treated for 1 month with these CA
inhibitors (CAIs) in mice with xenografts of a renal clear cell
carcinoma line, SK-RC-52, was observed.6a Such data show the
great promise of tumor growth inhibition with sulfonamides
acting as CA IX/XII inhibitors.1 The same group reported the
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ABSTRACT: A series of ureido-substituted benzenesulfona-
mides was prepared that showed a very interesting profile for
the inhibition of several human carbonic anhydrases (hCAs, EC
4.2.1.1), such as hCAs I and II (cytosolic isoforms) and hCAs IX
and XII (transmembrane, tumor-associated enzymes). Excel-
lent inhibition of all these isoforms has been observed with
various members of the series, depending on the substitution
pattern of the urea moiety. Several low nanomolar CA IX/XII
inhibitors also showing good selectivity for the transmembrane
over the cytosolic isoforms have been discovered. One of them,
4-{[(30-nitrophenyl)carbamoyl]amino}benzenesulfonamide,
significantly inhibited the formation of metastases by the highly
aggressive 4T1 mammary tumor cells at pharmacologic concentrations of 45 mg/kg, constituting an interesting candidate for the
development of conceptually novel antimetastatic drugs.
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proof-of-concept study showing that human monoclonal anti-
bodies targeting CA IX can also be used for imaging of hypoxic
tumors.6b The generation of high-affinity human monoclonal
antibodies (A3 and CC7) specific to hCA IX, using phage
technology, has been recently reported.6b These antibodies were
able to stain CA IX ex vivo and to target the cognate antigen
in vivo. In one studied animal model of colorectal cancer
(LS174T), CA IX imaging closely matched pimonidazole stain-
ing, with a preferential staining of tumor areas characterized by
little vascularity and low perfusion.6b The same conclusion has
been reached by our group by using small molecule CA IX
selective inhibitors of the type 1.3 Fluorescent sulfonamides 1
with a high affinity for CA IX have been developed and shown to
bind to cells only when CA IX protein was expressed and while
cells were hypoxic. NMRI-nu mice subcutaneously transplanted
with HT-29 colorectal tumors were treated with 7% oxygen or
with nicotinamide and carbogen and were compared with
control animals. Accumulation of compound 1 was monitored
by noninvasive fluorescent imaging. Specific accumulation of 1
could be observed in delineated tumor areas compared with a
structurally similar non-sulfonamide analogue incorporating the
same scaffold 2. Administration of nicotinamide and carbogen,
decreasing acute and chronic hypoxia, respectively, prevented
accumulation of 1 in the tumor. When treated with 7% oxygen
breathing, a 3-fold higher accumulation of 1 was observed.
Furthermore, the bound inhibitor fraction was rapidly reduced
upon tumor reoxygenation.3 Such in vivo imaging results confirm
previous in vitro data demonstrating that CAI binding and
retention require exposure to hypoxia. Labeled sulfonamide
CAIs may provide a powerful tool to visualize hypoxia response
in solid tumors. An important step was thus made toward clinical
applicability, indicating the potential of patient selection for CA
IX directed therapies.3
One main draw-back of classical sulfonamide CAIs (such as
AAZ) is the lack of selectivity for inhibiting CA IX over the other
CA isoforms present in humans (15 isoforms, CAs I-XIV, are
present in primates and 16 isoforms, i.e., CAs I-XV, in other
vertebrates).1 Thus, it is crucial to explore chemotypes posses-
sing amore selective inhibition profile against the target isoforms,
e.g., with selectivity for the inhibition of the tumor-associated
over other CA isoforms. A small series of five 4-RNHCONH-
substituted benzenesulfonamide derivatives was recently inves-
tigated as inhibitors of the cytosolic isoform hCA II (h = human)
by one of these groups.10 It has been observed that their potency
varied between 3.3 and 226 nM, and by means of X-ray crystal-
lography a highly variable orientation of the R-ureido moieties
was evidenced when the inhibitor was bound within the enzyme
active site (Figure 1).10 The R moieties were not disordered in
the X-ray crystal structures, but they adopted diverse orientations
based on their specific chemical nature (Figure 1). Furthermore,
a strong correlation has been observed between the binding
pattern and R group orientation and the CA II inhibitory
properties for this small library of compounds, where R was
4-fluorophenyl, pentafluorophenyl, 2-isopropylphenyl, 3-nitro-
phenyl, and cyclopentyl.10
In this paper we report the synthesis of a larger series of such
ureido-substituted sulfonamide CAIs that possess strong affinity
for CA IX, an acceptable selectivity profile for inhibiting the
tumor-associated isoforms CAs IX and XII over the cytosolic
ones CAs I and II, and excellent in vivo antimetastatic effects in a
breast cancer xenograft model.
’RESULTS AND DISCUSSION
Chemistry. In a recent work10 we showed that benzenesulfo-
namides incorporating 4-substituted ureido moieties act as hCA
II inhibitors with potencies that correlate well with the orienta-
tion of the R moiety present in the ureido tail of the compound
(Figure 1). As other classes of ureido-substituted benzenesulfo-
namides have been reported earlier,11,12 and we observed that
they may lead to isoform-selective compounds,12 we decided to
investigate in greater detail such derivatives. We report here the
synthesis of a large series of 4-ureidosubstituted-benzenesulfo-
namides 4-30 prepared by reaction of sulfanilamide 3with aryl/
alkyl isocyanates A1-A27 (Scheme 1). The chemical diversity
was generated by varying the nature of the starting isocyanate,
A1-A27 (Table 1). The CA isoforms have differing amino acid
sequences in the external portion of their active sites; therefore,
compounds with a better selectivity profile for the various
isoforms will contain an R group moiety that can interact with
this region.13 This has been reported earlier by our group,12 with
Figure 1. Binding of ureido-substituted benzenesulfonamides to the
hCA II active site. The benzenesulfonamide moiety of five inhibitors is
totally superposable, whereas the RNHCONH tails adopt different
orientations in various subpockets of the active site (R = 3-nitrophenyl,
violet; R = 2-isopropylphenyl, yellow; R = pentafluorophenyl, magenta;
R = 4-fluorophenyl, sky blue; R = cyclopentyl, gray).10 The PDB entries
of these structures are 3N4B, 3N0N, 3N3J, 3N2P, and 3MZL,
respectively.10
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the observation that some ureido-substituted sulfonamides show
selective inhibition of isoform hCA I over the dominant one
hCA II.
As shown in Scheme 1 and Table 1, a large variety of aromatic
and aliphatic R moieties have been incorporated in the new CAIs
4-30 reported here, in order to have an extensive structure-
activity relationship (SAR) insight regarding their interactions
with various CA isoforms with medicinal chemistry relevance.
The synthesis of such compounds is a one-step process, generally
occurring in high yield, allowing for the preparation of a large
number of derivatives. Most of the CAIs of sulfonamide type
investigated earlier contained CONH or SO2NH linkers be-
tween the sulfonamide head moiety and the tail instead of the
ureido one present in 4-30. These different linkers allow less
flexibility for the inhibitor scaffold, and this is probably the reason
why such sulfonamides bind in the cannonical hydrophobic
pocket of hCA II.13,14 They also generally do not show isoform
selectivity.10 In contrast, for derivatives incorporating the ureido
linker (of type 4-30), it has been shown10 that the tails (all of
them well ordered in the crystal structures; see Figure 1) are
found in various hydrophobic pockets of the CA II active site. As
seen from the crystallographic data (Figure 1),10 the torsion
angles between these two fragments of the scaffold were quite
different for the five compounds investigated by X-ray crystal-
lography (i.e., 7, 13, 16, 25, and 28).10 This probably allows the
flexibility of the inhibitor to select the hydrophobic subpocket in
such a way to avoid steric clashes10,13,14 and to make as many as
possible favorable interactions with amino acid residues within
the enzyme cavity.
CA Inhibition. Inhibition of four physiologically relevant
R-CA isoforms with compounds 4-30 and acetazolamide
(5-acetamido-1,3,4-thiadiazole-2-sulfonamide, AZA, a clinically
used drug) is presented in Table 1.15 hCAs I and II (cytosolic,
widespread enzymes) and hCAs IX and XII (transmembrane,
tumor-associated CAs) have been included in this study because
of their relevance as targets/offtargets when developing CAIs.
Indeed, CA II for example is the drug target for developing
antiglaucoma CAIs,1 but it is an off-target when considering CA
IX/XII inhibition.1-3 In this latter case, only the transmembrane,
tumor-associated isozymes (IX and XII) should be inhibited, as
CA II may have the function of housekeeping enzyme and its
inhibition may lead to side effects.1-3
The following structure-activity relationship (SAR) can be
observed from data of Table 1 for the series of ureidosulfona-
mides 4-30 investigated here.
(i) The slow cytosolic isoform hCA I was inhibited by
compounds 4-30 with a wide range of potency, with inhibition
constants in the range 9.0-5530 nM. Potent hCA I inhibition
has been observed with the following compounds: 11, 16, 19, 22,
and 30. These compounds incorporate 2- or 4-substuted phenyl
moieties (such as 4-trifluoromethylphenyl, 2-isopropylphenyl,
4-n-butoxyphenyl, and 2-cyanophenyl) except 30 which
possesses an indane moiety. It is thus clear, as in the crystal-
lographic work reported earlier10 for 5 of the 27 derivatives
reported here, that the nature of the R moiety present in these
ureidosulfonamiodes is the main player influencing potency
against all investigated CA isoforms. Indeed, a number of these
derivatives, including 5, 6, 14, 4, 25, and 26, behaved as medium
potency hCA I inhibitors with KI in the range 23.4-92 nM.
Again the nature of the R moieties present in these compounds
was rather variable (benzyl, diphenylmethyl, and 2-, 3-, or
4-substituted phenyls). The remaining derivatives showed a
decreased affinity for hCA I, with KI in the range 388-5530
nM. AAZ is similar to these compounds, with an inhibition
constant of 250 nM against hCA I (Table 1).
Scheme 1. Preparation of the 4-Ureidosubstituted Benzene-
sulfonamides 4-30 from Sulfanilamide 3 and Isocyanates
A1-A27
Table 1. Inhibition of hCAs I and II (Cytosolic Isoforms) and
hCAs IX and XII (Transmembrane, Tumor-Associated En-
zymes) with Ureidosulfonamides 4-30 and Acetazolamide
AAZ as Standard15
KI (nM)
compd R hCA I hCA II hCA IX hCA XII
4 Ph 760 3730 575 67.3
5 PhCH2 92 2200 41.4 49.5
6 Ph2CH 83 3725 58.8 64.5
7 4-FC6H4 5080 96 45.1 4.5
8 Cl-FC6H4 2150 781 58.0 5.3
9 4-BrC6H4 1465 1290 69.3 7.9
10 4-IC6H4 5500 2634 24.5 4.3
11 4-CF3C6H4 9.7 1150 6.2 2.3
12 3,5-(CF3)2C6H3 3690 75 53 39
13 C6F5 2395 50 5.4 5.1
14 2-MeOC6H4 92 4070 465 61.2
15 4-AcC6H4 388 1060 5.4 4.6
16 2-i-PrC6H4 9.0 3.3 0.5 4.2
17 4-i-PrC6H4 4330 5005 541 49.7
18 4-n-BuC6H4 5530 2485 376 28.5
19 4-n-BuOC6H4 11.3 2.1 0.8 2.5
20 4-n-octyl-C6H4 536 9600 47.1 52.8
21 4-NCC6H4 57.0 64.7 6.0 6.5
22 2-NCC6H4 10.9 2.4 0.3 4.6
23 4-PhOC6H4 604 85 69.1 7.1
24 2-PhC6H4 1170 9.7 65.7 65.1
25 3-O2NC6H4 23.4 15 0.9 5.7
26 4-MeO-2-MeC6H3 89.2 3310 73.3 6.0
27 9H-fluoren-2-yl 1700 908 102 55.4
28 cyclopentyl 470 226 7.3 7.0
29 3,5-Me2C6H3 6530 1765 6.9 6.2
30 indan-5-yl 9.8 8.9 7.0 2.5
AAZ 250 12 25 5.7
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(ii) The second offtarget isoform, the cytosolic hCA II, has also
been inhibited with potencies ranging from the low nanomolar to
the micromolar by ureidosulfonamides 4-30 (Table 1). Thus,
compounds 16, 19, 22, 24, and 30 were very potent hCA II
inhibitors, with KI in the range 2.1-9.7 nM. These derivatives
incorporate 2- or 4-substituted phenyl moieties or the indane ring.
It is interesting to note that 16 and 19 contain in theirmolecule the
rather bulky, lipophilic i-Pr, n-BuO, or biphenyl moieties, which
one could consider to be too bulky to fit well within the hCA II
active site. However, as shown here and in the crystallographic,
preliminary communication,10 the i-Pr moiety of 16 makes
hydrophobic contacts in a patch within the enzyme active site
never seen earlier to accommodate inhibitors, also making a
stacking with Phe131. This particular binding mode thus explains
the excellent hCA II inhibitory of 16. However, four other
derivatives of the series investigated here, i.e., 7, 13, 25, and 28,
exploited different binding pockets within the enzyme active site10
and also possessed diverse inhibitory power. Another series of
compounds showed medium potency hCA II inhibition, with KI
in the range 15-96 nM. These compounds (7, 12, 13, 21, 23, and
25) also possess aromatic groups at the second nitrogen ureido
group, such as 4-fluorophenyl, 3,5-di(trifluoromethyl)phenyl,
pentafluorophenyl, 4-cyanophenyl, 4-phenoxyphenyl, or 3-nitro-
phenyl. The remaining derivatives showed lower hCA II inhibitory
properties, withKI in the range 226-9600 nM. The least effective
hCA II inhibitor was the derivative incorporating the long 4-n-
octylphenyl moiety (20).
(iii) The tumor-associated hCA IX was generally better
inhibited by these compounds compared to hCAs I and II
discussed above, with KI in the range 0.3-575 nM. Compounds
such as 11, 13, 15, 16, 19, 21, 22, 25, 28, and 29 showed excellent
hCA IX inhibiting properties, withKI in the range 0.3-7.3 nM. A
few weak hCA IX inhibitors were detected (e.g., 4, 14, 18, and
27), with KI in the range 102-575 nM, whereas all other
derivatives presented inhibition constants of <100 nM. Substitu-
tion patterns favorable to potent hCA IX inhibition include the
presence of 4-trifluoromethylphenyl, pentafluorophenyl, 4-ace-
tylphenyl, 2-isopropylphenyl, 4-n-butoxyphenyl, 2- and 4-cyano-
phenyl, 3-nitrophenyl, cyclopentyl, and 3,5-dimethylphenyl
moieties. However, most of the other substitution patterns
present in the remaining compounds lead to effective hCA IX
inhibitors, with KI in the range 24.5-73.3 nM. AAZ was an
effective hCA IX inhibitor too, with a KI of 25 nM (Table 1).
(iv) hCAXII was also effectively inhibited by sulfonamides 4-
30, with KI in the range 2.3-67.3 nM. This was the isoform with
the highest affinity for these compounds, as most of them were
excellent inhibitors. Inhibition constants of <10 nM have been
observed with a rather large number of compounds, among
which are 7-11, 13, 15, 16, 19, 21, 25, 26, 28-30, and AAZ.
Thus, many substitution patterns lead to very effective hCA XII
inhibitors in this congeneric series investigated here. The ex-
cellent inhibition of all CA isoforms investigated here and also
the variability in inhibitory power for the various members of this
congeneric series are phenomena never observed earlier for any
class of CAIs investigated in detail and are probably due to the
presence of the ureido linker in these molecules, which leads to
the binding of the compound in multiple ways to the enzymes
active sites.
(v) The selectivity ratio for inhibiting the target over the
offtarget isoforms for this congeneric series of sulfonamides
is rather complex because of the factors mentioned above.
However, some interesting findings emerged. For example,
compound 15 has a selectivity ratio of 71.8 for inhibiting CA
IX over CA I and of 196.3 for inhibiting CA IX over CA II (the
corresponding ratios for inhibiting CA XII over CAs I and II are
even better), thus being a selective inhibitor of the tumor-
associated isoforms over the cytosolic ones. Compound 25 was
a stronger inhibitor of the cytosolic isoforms compared to 15 and
had good selectivity ratio for inhibiting the tumor-associated
isoforms over the cytosolic isoforms.
Antimetastatic Effects of CA IX Inhibitors. CA IX is highly
expressed in breast malignancies,16 and studies have demon-
strated that CA IX and CA XII are variably expressed in breast
cancer cell lines.8 Furthermore, CA IX is associated with a poor
prognosis for patients with breast cancer17 and it is significantly
associated with distant metastasis (Lou et al., unpublished
results). Therefore, we have chosen breast cancer as amalignancy
model in which to test, in vivo, the antimetastatic activity of some
of the CA IX inhibitors described here. Specifically, we have used
the 4T1 syngeneic mouse mammary tumor model.18 4T1 cells
are highly tumorigenic and metastasize spontaneously to multi-
ple sites in a manner similar to that for human breast cancer
following orthotopic implantation into an immunocompetent
host.18,19 We have shown recently that 4T1 tumors overexpress
CA IX20 and that these cells induce CA IX during hypoxia in vitro
(Lou et al., unpublished results). These attributes make the 4T1
mouse mammary tumor cells a good model in which to examine
the effects of inhibiting CA IX activity on breast cancer
metastasis.
Although the 4T1 tumor model can be used to evaluate
spontaneous metastatic events subsequent to tumor implanta-
tion and growth, such studies are lengthy and require surgical
removal of the primary tumor. Because we were interested in
evaluating the effect of the compounds on metastasis specifically,
we elected to test the inhibitors using an experimental metastasis
approach. Two compounds were chosen for the in vivo studies,
15 and 25, both of which show good CA IX and XII inhibitory
activities and acceptable selectivity ratios for inhibiting the
tumor-associated over the cytosolic isoforms, as discussed above.
We injected 4T1 cells expressing luciferase intravenously and
assessed the ability of the cells to form lung metastases after
treating with compounds 15 (Figure 2) and 25 (Figure 3) using
bioluminescent imaging techniques. Mice were treated with the
inhibitors or equal amounts of vehicle beginning 24 h after
injection of cells, and metastases were imaged the day following
the final dose of inhibitor. We found that whereas treatment
with 15 was not able to decrease the metastatic burden relative
to the vehicle control group (Figure 2), treatment with 25
was effective in limiting colonization of the cells in the lungs in
a dose-dependent fashion (Figure 3). Quantification of the
bioluminescent signal revealed a statistically significant decrease
in the formation of metastases in the mice administered 25
(Figure 3), while no significant differences were observed among
the vehicle and 15-treated groups (Figure 2). Importantly,
administration of the inhibitors did not result in significant
weight loss in any animals, indicating that the inhibitors were
not generally toxic (Supporting Information Figure 1). These
data show that some of the ureidosulfonamide inhibitors of CA
IX reported here are effective in attenuating formation of
metastases in a model of aggressive breast cancer. It is interesting
to note that even if 15 and 25 showed comparable CA inhibitory
activity in vitro, 15 was ineffective in vivo probably because of
pharmacokinetic reasons. The pharmacokinetic evaluation for
some of these derivatives is in a preliminary stage, but we suspect
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that the acetyl moiety of 15may undergo metabolic oxidation to
the corresponding carboxylate followed by its conjugation and
rapid elimination, which may explain its lack of antimetastatic
effects compared to the highly efective 25 which is metabolically
stable.
’CONCLUSIONS
We report here a series of sulfonamides prepared by reaction
of sulfanilamide with aryl/alkyl isocyanates. The ureido-substi-
tuted benzenesulfonamides showed a very interesting profile for
the inhibition of hCAs I and II (cytosolic, off-target isoforms)
and hCAs IX and XII (transmembrane, tumor-associated en-
zymes). The structure-activity relationship for this class of
inhibitors was rather complex, but the main features associated
with effective inhibition of all theseR-CAs investigated here have
been delineated in detail. The nature of the Rmoiety substituting
the second ureido nitrogen is the main player in controlling the
inhibitory power, probably because of the flexibility of the ureido
linker and the possibility of the R group to orientate in different
subpockets of the active site cavity of these enzymes. The
compounds possessing as R moiety 4-trifluoromethylphenyl,
2-isopropylphenyl, 2-cyanophenyl, or indan-5-yl were effective
hCA I inhibitors with inhibition constants in the range 9.0-10.9
nM. The best hCA II inhibitor was the 2-isopropylphenyl-
substituted compound (KI of 3.3 nM), whereas many low
nanomolar and subnanomolar hCA IX/XII inhibitors were
obtained (e.g., R = 4-trifluoromethylphenyl, pentafluorophenyl,
4-acetylphenyl, 4-n-butoxyphenyl, 2-cyanophenyl, 3-nitrophenyl,
cyclopentyl, indan-5-yl, etc.). One of them, 4-{[(30-nitrophe-
nyl)carbamoyl]amino}benzenesulfonamide, strongly inhibited
the formation of metastases by the highly aggressive 4T1 mam-
mary tumor cells at pharmacologic concentrations of 15-45
mg/kg, constituting thus an interesting candidate for the devel-
opment of conceptually novel antimetastatic drugs.
’EXPERIMENTAL PROTOCOLS
Chemistry. 1H, 13C, and 19F spectra were recorded using a Bruker
Advance III 400 MHz spectrometer. The chemical shifts are reported in
parts per million (ppm), and the coupling constants (J) are expressed in
hertz (Hz). Infrared spectra were recorded on a Perkin-Elmer Spectrum
R XI spectrometer as solids on KBr plates. Melting points (mp) were
measured in open capillary tubes, unless otherwise stated, using a B€uchi
B-540 melting point apparatus and are uncorrected. Thin layer chro-
matography (TLC) was carried out on Merck silica gel 60 F254
aluminum backed plates. Elution of the plates was carried out using
ethyl acetate/petroleum ether as the eluting system. Visualization was
achieved with UV light at 254 nm by dipping into a ninhydrin TLC stain
solution and heating with a hot air gun. Flash column chromatography
was carried out using silica gel (obtained from Aldrich Chemical Co.,
Milan, Italy). The crude product was introduced into the column as a
solution in the same elution solvent system. Solvents and chemicals
were used as supplied from Aldrich Chemical Co., Milan, Italy. Purity
of the obtained compounds was assessed by HPLC and elemental
analysis (C, H, N) and was >95% for all of the new derivatives
reported here.
General Procedure for the Preparation of Compounds
4-30. Sulfanilamide 3 (2.90 mmol) was dissolved in acetonitrile (20-
30 mL) and then treated with a stoichiometric amount of isocyanates
A1-A27. The mixture was stirred at room temperature or heated at
50 C for 2 h, until completion (TLC monitoring). The heavy pre-
cipitate formed was filtered off, washed with diethyl ether (100 mL),
and dried in vacuo. All compounds described here were characterized
in detail by spectrosopic and analytic methods (see Supporting
Information).
4-{([(40-Acetylphenyl)amino]carbonyl)amino}benzenes-
ulfonamide (15). White solid; mp 258-260 C; silica gel TLC
Rf = 0.27 (ethyl acetate/petroleum ether 33%); νmax (KBr) cm
-1,
3300 (N-H urea), 1659 (CdO urea), 1590 (aromatic); δH (400 MHz,
DMSO-d6) 2.56 (3H, s, CH3), 7.26 (2H, s, SO2NH2), 7.64 (2H, d,
J = 8.8, 2 20-H), 7.67 (2H, d, J = 8.8, 2 3-H), 7.79 (2H, d, J = 8.8, 2
2-H), 7.96 (2H, d, J = 8.8, 2  30-H), 9.22 (1H, s, NH), 9.25 (1H, s,
NH); δC (100 MHz, DMSO-d6) 197.3 (CdO), 152.9 (CdO urea),
144.9, 143.4, 138.2, 131.7, 130.6, 127.8, 118.7, 118.4, 27.3 (CH3); m/z
(ESIþ): 344.36 [M þ H]þ, 356.34 [M þ Na]þ. C atom numbering is
as for 4.
4-{[(30-Nitrophenyl)carbamoyl]amino}benzenesulfona-
mide (25). Yellow solid; 44.3% yield; mp 246-248 C; silica gel TLC
Rf = 0.39 (ethyl acetate/petroleum ether 33%); νmax (KBr) cm
-1, 3370
(N-H urea), 1709 (CdO urea), 1592 (aromatic); δH (400 MHz,
DMSO-d6) 7.23 (2H, s, SO2NH2), 7.59 (1H, dd, J 8.4 8.0, 50-H), 7.65
(2H, d, J = 9.0, 2 3-H), 7.73 (1H, ddd, J = 8.4 2.0, 0.8, 60-H), 7.76 (2H,
d, J = 9.0, 2 2-H), 7.86 (1H, ddd, J = 8.0 2.4 0.8, 40-H), 8.58 (1H, appt,
J = 2.2, 20-H), 9.25 (1H, s, NH), 9.35 (1H, s, NH); δC (100 MHz,
Figure 2. Ureidosulfonamide 15 did not reduce the formation of
metastases by 4T1 mammary tumor cells. (A) 4T1 cells were injected
directly into the tail vein of BALB/c mice. Mice then received vehicle or
15 starting 24 h after injection of cells. Animals received therapy every
day, and five doses were provided. Bioluminescent images were acquired
24 h after the final dose of inhibitor. (B) Quantification of biolumines-
cence: n = 6 per group. No significant differences were observed among
the vehicle inhibitor-treated groups.
Figure 3. Ureidosulfonamide 25 inhibits the formation of metastases by
4T1 mammary tumor cells. (A) 4T1 cells were injected directly into the
tail vein of BALB/c mice. Mice then received vehicle or 25 starting 24 h
after injection of cells. Animals received therapy every other day, and
three doses were provided. Bioluminescent images were acquired 24 h
after the final dose of inhibitor. (B) Quantification of bioluminescence:
n = 4 per group; /, p < 0.05.
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DMSO-d6) 153.2 (CdO urea), 149.1, 143.3, 141.6, 138.3, 131.1, 127.7,
125.5, 118.8, 117.6, 113.3; m/z (ESIþ): 359.23 [M þ Na]þ.
CA Inhibition. An Applied Photophysics stopped-flow instrument
was used for assaying the CA catalyzed CO2 hydration activity.
15 Phenol
red (at 0.2 mM) was used as indicator, working at the absorbance
maximum of 557 nm, with 20 mM Hepes (pH 7.4) and 20 mM NaBF4
(for maintaining constant the ionic strength), following the initial rates
of the CA-catalyzed CO2 hydration reaction for 10-100 s. The CO2
concentrations ranged from 1.7 to 17 mM for the determination of the
kinetic parameters and inhibition constants. For each inhibitor, at least
six traces of the initial 5-10% of the reaction were used for determining
the initial velocity. The uncatalyzed rates were determined in the same
manner and subtracted from the total observed rates. Stock solutions of
inhibitor (10 mM) were prepared in distilled-deionized water, and
dilutions up to 0.01 nM were done thereafter with distilled-deionized
water. Inhibitor and enzyme solutions were preincubated together for
15 min at room temperature prior to assay in order to allow for the
formation of the E-I complex. The inhibition constants were obtained
by nonlinear least-squares methods using PRISM 3, whereas the kinetic
parameters for the uninhibited enzymes were from Lineweaver-Burk
plots, as reported earlier,3 and represent the mean from at least three
different determinations.
Pharmacological Inhibitors. For in vivo studies, compound 25
was solubilized in 37.5% PEG400/12.5% ethanol/50% saline prior to
injection, while compound 15 was solubilized in 37.5% PEG400/12.5%
ethanol/10% Cremophor/40% saline. Drug aliquots were made fresh
daily from powder. Drugs were administered by ip injection using a
volume of 200 μL for a 20 g mouse. Specific dosing schedules are
described in the appropriate figures.
Experimental Metastasis Assay. All animal studies and proce-
dures were carried out in accordance with protocols approved by the
Institution Animal Care Committee at the BC Cancer research Centre
and the University of British Columbia (Vancouver, Canada). 4T1 cells
(5  105/mouse) were injected directly into the tail vein of 7-9 week-
old female BALB/c mice. Metastatic burden was monitored and
quantified using bioluminescent imaging as previously described.21
Briefly, mice were imaged 24 h following the final dose of a given
compound. Images showing tumor burden are displayed using a log scale
color range, and data were quantified using images acquired for 1 min at
a binning level of 8. Data were analyzed using the contour ROI feature in
the Living Image software (Xenogen). Results were subjected to
statistical analysis using the Data Analysis ToolPack in Excel software.
Two-tailed p values were calculated using Student’s t test. Data were
considered significant for p < 0.05.
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